

Giovanni Tarantino

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1317457/giovanni-tarantino-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

124
papers

3,672
citations

36
h-index

56
g-index

137
ext. papers

4,199
ext. citations

4.3
avg, IF

5.75
L-index

#	Paper	IF	Citations
124	Copper-catalyzed dicarbonyl stress in NAFLD mice: protective effects of Oleuropein treatment on liver damage.. <i>Nutrition and Metabolism</i> , 2022 , 19, 9	4.6	
123	A Comparative Study of the Triglycerides/HDL Ratio and Pseudocholinesterase Levels in Patients with Bladder Cancer.. <i>Diagnostics</i> , 2022 , 12,	3.8	3
122	PaO ₂ /FiO ₂ ratio forecasts COVID-19 patients Outcome regardless of age: a cross-sectional, monocentric study. <i>Internal and Emergency Medicine</i> , 2021 , 1	3.7	3
121	New Avenues for Treatment and Prevention of Drug-Induced Steatosis and Steatohepatitis: Much More Than Antioxidants. <i>Advances in Therapy</i> , 2021 , 38, 2094-2113	4.1	2
120	Liver-spleen axis in nonalcoholic fatty liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021 , 15, 759-769	4.2	2
119	Age and Interleukin-15 Levels Are Independently Associated With Intima-Media Thickness in Obesity-Related NAFLD Patients. <i>Frontiers in Medicine</i> , 2021 , 8, 634962	4.9	11
118	Association of NAFLD and Insulin Resistance with Non Metastatic Bladder Cancer Patients: A Cross-Sectional Retrospective Study. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	18
117	Clinical factors affecting prostate-specific antigen levels in prostate cancer patients undergoing radical prostatectomy: a retrospective study. <i>Future Science OA</i> , 2021 , 7, FSO643	2.7	4
116	Findings from Studies Are Congruent with Obesity Having a Viral Origin, but What about Obesity-Related NAFLD?. <i>Viruses</i> , 2021 , 13,	6.2	4
115	Copper concentrations are prevalently associated with antithrombin III, but also with prothrombin time and fibrinogen in patients with liver cirrhosis: A cross-sectional retrospective study. <i>Journal of Trace Elements in Medicine and Biology</i> , 2021 , 68, 126802	4.1	
114	It Is High Time Physicians Thought of Natural Products for Alleviating NAFLD. Is There Sufficient Evidence to Use Them?. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	7
113	Could SCGF-Beta Levels Be Associated with Inflammation Markers and Insulin Resistance in Male Patients Suffering from Obesity-Related NAFLD?. <i>Diagnostics</i> , 2020 , 10,	3.8	29
112	Troponin Levels Relate to CRP Concentrations in Patients With NAFLD on Maintenance Haemodialysis: A Retrospective Study. <i>Advances in Therapy</i> , 2020 , 37, 3337-3347	4.1	4
111	Oleuropein overrides liver damage in steatotic mice. <i>Journal of Functional Foods</i> , 2020 , 65, 103756	5.1	7
110	Recreational Drugs: a New Health Hazard for Patients with Concomitant Chronic Liver Diseases. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020 , 23, 79-84	1.4	12
109	Gastrointestinal peptides and nonalcoholic fatty liver disease. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2020 , 27, 11-15	4	4
108	Is There a Link between Basal Metabolic Rate, Spleen Volume and Hepatic Growth Factor Levels in Patients with Obesity-Related NAFLD?. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	6

107	Do Transferrin Levels Predict Haemodialysis Adequacy in Patients with End-Stage Renal Disease?. <i>Nutrients</i> , 2019 , 11,	6.7	4
106	Nonalcoholic Fatty Liver Disease: A Challenge from Mechanisms to Therapy. <i>Journal of Clinical Medicine</i> , 2019 , 9,	5.1	75
105	Suggestive hypothesis on a case report: Patient presenting with cyclical ovarian cysts coupled to increased cholestatic enzymes. <i>Journal of Obstetrics and Gynaecology Research</i> , 2019 , 45, 477-481	1.9	
104	Interferon-alpha 2 but not Interferon-gamma serum levels are associated with intramuscular fat in obese patients with nonalcoholic fatty liver disease. <i>Journal of Translational Medicine</i> , 2019 , 17, 8	8.5	11
103	Prediction of carotid intima-media thickness in obese patients with low prevalence of comorbidities by serum copper bioavailability. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018 , 33, 1511-1517	15.17	30
102	Comparison of the everolimus concentrations measured in whole blood with everolimus QMS or sirolimus CMIA. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2018 , 78, 275-280	2	0
101	Phenotyping of CYP 4501A2 Activity by Total Overnight Salivary Caffeine Assessment (TOSCA) in Patients on Warfarin Treatment: A Cross-Sectional Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018 , 24, 928-935	3.3	2
100	Hematocrit Values Predict Carotid Intimal-Media Thickness in Obese Patients With Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study. <i>Frontiers in Endocrinology</i> , 2018 , 9, 203	5.7	5
99	Nutrition, inflammation and liver-spleen axis. <i>Critical Reviews in Food Science and Nutrition</i> , 2018 , 58, 3141-3158	11.5	38
98	Oleuropein Induces AMPK-Dependent Autophagy in NAFLD Mice, Regardless of the Gender. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	25
97	Adherence to the Mediterranean Diet and Circulating Levels of Sirtuin 4 in Obese Patients: A Novel Association. <i>Oxidative Medicine and Cellular Longevity</i> , 2017 , 2017, 6101254	6.7	31
96	Reticulocyte Hemoglobin Content Helps Avoid Iron Overload in Hemodialysis Patients: A Retrospective Observational Study. <i>In Vivo</i> , 2017 , 31, 709-712	2.3	3
95	Lipids Nutrition and Epigenetic Modification in Obesity-Related Co-Morbidities * *All authors equally contributed to draft the manuscript. All authors gave final approval of the version to be published. Disclosure statement: The authors declare that there are no conflicts of interest. 2016 , 85-110		0
94	Serum levels of Lp(a) are related to waist circumference in NAFLD patients with low prevalence of co-morbidities. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2016 , 76, 544-552	2	2
93	Lipids, Low-Grade Chronic Inflammation and NAFLD 2016 , 731-759		
92	Sublingual administration improves systemic exposure of tacrolimus in kidney transplant recipients: comparison with oral administration. <i>European Journal of Clinical Investigation</i> , 2016 , 46, 651-7	4.6	5
91	Nutrition: a key environmental dietary factor in clinical severity and cardio-metabolic risk in psoriatic male patients evaluated by 7-day food-frequency questionnaire. <i>Journal of Translational Medicine</i> , 2015 , 13, 303	8.5	46
90	Successful and Safe Long-Term Standard Antiviral Therapy in a Patient with "Explosive" Immune Response in Course of HCV-Related Liver Cirrhosis. <i>International Journal of Molecular Sciences</i> , 2015 , 16, 14075-85	6.3	5

89	Systematic review on intervention with prebiotics/probiotics in patients with obesity-related nonalcoholic fatty liver disease. <i>Future Microbiology</i> , 2015 , 10, 889-902	2.9	79
88	Bisphenol-A plasma levels are related to inflammatory markers, visceral obesity and insulin-resistance: a cross-sectional study on adult male population. <i>Journal of Translational Medicine</i> , 2015 , 13, 169	8.5	72
87	Preliminary data on the relationship between circulating levels of Sirtuin 4, anthropometric and metabolic parameters in obese subjects according to growth hormone/insulin-like growth factor-1 status. <i>Growth Hormone and IGF Research</i> , 2015 , 25, 28-33	2	25
86	Hype or Reality: Should Patients with Metabolic Syndrome-related NAFLD be on the Hunter-Gatherer (Paleo) Diet to Decrease Morbidity?. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2015 , 24, 359-68	1.4	19
85	Nonalcoholic fatty liver disease, spleen and psoriasis: New aspects of low-grade chronic inflammation. <i>World Journal of Gastroenterology</i> , 2015 , 21, 6892-7	5.6	31
84	Is serum Interleukin-17 associated with early atherosclerosis in obese patients?. <i>Journal of Translational Medicine</i> , 2014 , 12, 214	8.5	47
83	Circulating levels of sirtuin 4, a potential marker of oxidative metabolism, related to coronary artery disease in obese patients suffering from NAFLD, with normal or slightly increased liver enzymes. <i>Oxidative Medicine and Cellular Longevity</i> , 2014 , 2014, 920676	6.7	44
82	Could the improvement of obesity-related co-morbidities depend on modified gut hormones secretion?. <i>World Journal of Gastroenterology</i> , 2014 , 20, 16649-64	5.6	23
81	Mammalian Target of Rapamycin in Inflammatory Skin Conditions. <i>European Journal of Inflammation</i> , 2014 , 12, 341-350	0.3	14
80	Beyond Nutrition Is There Any Role for Physical Activity in Nonalcoholic Fatty Liver Disease Therapy? 2014 , 79-87		
79	Nutrition: a promising route for prevention and management of obesity-related nonalcoholic fatty liver disease. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2014 , 20, 39-41	1.3	3
78	Carotid intima-media thickness is predicted by combined eotaxin levels and severity of hepatic steatosis at ultrasonography in obese patients with Nonalcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2014 , 9, e105610	3.7	22
77	What non-alcoholic fatty liver disease has got to do with obstructive sleep apnoea syndrome and viceversa?. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2014 , 23, 291-9	1.4	4
76	Nesfatin-1: role as possible new anti-obesity treatment. <i>EXCLI Journal</i> , 2014 , 13, 586-91	2.4	6
75	Non-alcoholic fatty liver disease, diet and gut microbiota. <i>EXCLI Journal</i> , 2014 , 13, 461-90	2.4	14
74	Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease?. <i>World Journal of Gastroenterology</i> , 2014 , 20, 9217-28	5.6	47
73	Should visceral fat, strictly linked to hepatic steatosis, be depleted to improve survival?. <i>Hepatology International</i> , 2013 , 7, 413-28	8.8	10
72	Should visceral fat be reduced to increase longevity?. <i>Ageing Research Reviews</i> , 2013 , 12, 996-1004	12	69

71	Bisphenol A in polycystic ovary syndrome and its association with liver-spleen axis. <i>Clinical Endocrinology</i> , 2013 , 78, 447-53	3.4	65
70	Inhibition of the mTOR pathway: a possible protective role in coronary artery disease. <i>Annals of Medicine</i> , 2013 , 45, 348-56	1.5	73
69	"Obesity paradox" or "metabolically benign obesity"?. <i>Eating and Weight Disorders</i> , 2013 , 18, 337-8	3.6	4
68	Is Assessing the Presence of NASH by Liver Histology or Surrogate Markers Always Advisable?. <i>Hepatitis Monthly</i> , 2013 , 13, e7560	1.8	5
67	Noninvasive assessment of liver fibrosis in patients with chronic hepatitis C (and congenital bleeding disorders): where do we stand?. <i>Seminars in Thrombosis and Hemostasis</i> , 2013 , 39, 803-15	5.3	4
66	Liver-spleen axis: intersection between immunity, infections and metabolism. <i>World Journal of Gastroenterology</i> , 2013 , 19, 3534-42	5.6	85
65	Effects of Ambient Air Pollution on Birth Outcomes: An Overview. <i>Critical Reviews in Environmental Science and Technology</i> , 2013 , 43, 752-774	11.1	9
64	Effects of Ambient Air Pollution on Birth Outcomes: An Overview. <i>Critical Reviews in Environmental Science and Technology</i> , 2013 , 43, 1223-1245	11.1	12
63	Polycystic Ovary Syndrome and Hepatic Steatosis: Could Low-Grade Chronic Inflammation Be Mediated by the Spleen?. <i>European Journal of Inflammation</i> , 2013 , 11, 179-191	0.3	3
62	What does irritable bowel syndrome share with non-alcoholic fatty liver disease?. <i>World Journal of Gastroenterology</i> , 2013 , 19, 5402-20	5.6	15
61	Exposure to ambient air particulate matter and non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2013 , 19, 3951-6	5.6	31
60	What about non-alcoholic fatty liver disease as a new criterion to define metabolic syndrome?. <i>World Journal of Gastroenterology</i> , 2013 , 19, 3375-84	5.6	117
59	Endocrine changes (beyond diabetes) after bariatric surgery in adult life. <i>Journal of Endocrinological Investigation</i> , 2013 , 36, 267-79	5.2	4
58	Pathogenesis of hepatic steatosis: the link between hypercortisolism and non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2013 , 19, 6735-43	5.6	51
57	What is the role of adiponectin in obesity related non-alcoholic fatty liver disease?. <i>World Journal of Gastroenterology</i> , 2013 , 19, 802-12	5.6	130
56	Are hepatic steatosis and carotid intima media thickness associated in obese patients with normal or slightly elevated gamma-glutamyl-transferase?. <i>Journal of Translational Medicine</i> , 2012 , 10, 50	8.5	43
55	Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2012 , 18, 5839-47	5.6	121
54	Hepatic steatosis, carotid plaques and achieving MDA in psoriatic arthritis patients starting TNF- α blockers treatment: a prospective study. <i>Arthritis Research and Therapy</i> , 2012 , 14, R211	5.7	28

53	Hepatic steatosis and disease activity in subjects with psoriatic arthritis receiving tumor necrosis factor- β blockers. <i>Journal of Rheumatology</i> , 2012 , 39, 1042-6	4.1	32
52	Hepatitis C virus-related arthritis and rheumatoid arthritis: could they be different aspects of the same disease?. <i>International Journal of Immunopathology and Pharmacology</i> , 2012 , 25, 293-6	3	0
51	Synchronous Onset of Secondary Raynaud $\text{\textcircled{R}}$ Phenomenon in Monozygotic Twins. <i>European Journal of Inflammation</i> , 2012 , 10, 535-537	0.3	
50	Similar serum levels of IL-6 and its soluble receptors in patients with HCV-related arthritis and rheumatoid arthritis: a pilot study. <i>International Journal of Immunopathology and Pharmacology</i> , 2012 , 25, 281-5	3	10
49	Have guidelines addressing physical activity been established in nonalcoholic fatty liver disease?. <i>World Journal of Gastroenterology</i> , 2012 , 18, 6790-800	5.6	52
48	Is visceral fat reduction necessary to favour metabolic changes in the liver?. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2012 , 21, 205-8	1.4	14
47	Is there any consensus as to what diet or lifestyle approach is the right one for NAFLD patients?. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2012 , 21, 293-302	1.4	33
46	Abnormally high prevalence of major components of the metabolic syndrome in subjects with early-onset idiopathic venous thromboembolism. <i>Thrombosis Research</i> , 2011 , 127, 193-7	8.2	34
45	Serum Bcl-2 concentrations in overweight-obese subjects with nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2011 , 17, 5280-8	5.6	52
44	Analytical and pharmacological aspects of therapeutic drug monitoring of mTOR inhibitors. <i>Current Drug Metabolism</i> , 2011 , 12, 253-67	3.5	22
43	Urinary excretion of 5-hydroxy-3-indoleacetic acid in dystimic/depressed, adult obese women: what correlations to hepatic steatosis?. <i>International Journal of Immunopathology and Pharmacology</i> , 2011 , 24, 769-79	3	11
42	Serum 25-Hydroxyvitamin D Levels, phosphoprotein enriched in diabetes gene product (PED/PEA-15) and leptin-to-adiponectin ratio in women with PCOS. <i>Nutrition and Metabolism</i> , 2011 , 8, 84	4.6	24
41	Liver-spleen axis, insulin-like growth factor-(IGF)-I axis and fat mass in overweight/obese females. <i>Journal of Translational Medicine</i> , 2011 , 9, 136	8.5	41
40	Insulin-like Growth Factor-1, Psoriasis, and Inflammation: A M $\text{\textcircled{R}}$ age $\text{\textcircled{R}}$ trois?. <i>European Journal of Inflammation</i> , 2011 , 9, 277-283	0.3	3
39	Evalutation of mycophenolic acid systemic exposure by limited sampling strategy in kidney transplant recipients receiving enteric-coated mycophenolate sodium (EC-MPS) and cyclosporine. <i>Nephrology Dialysis Transplantation</i> , 2011 , 26, 3019-25	4.3	25
38	Is spleen circulation impaired in systemic sclerosis and what is the role of liver fibrosis?. <i>World Journal of Gastroenterology</i> , 2011 , 17, 1606-13	5.6	5
37	Spleen: A new role for an old player?. <i>World Journal of Gastroenterology</i> , 2011 , 17, 3776-84	5.6	85
36	JNKs, insulin resistance and inflammation: A possible link between NAFLD and coronary artery disease. <i>World Journal of Gastroenterology</i> , 2011 , 17, 3785-94	5.6	98

35	Circulating levels of cytochrome C, gamma-glutamyl transferase, triglycerides and unconjugated bilirubin in overweight/obese patients with non-alcoholic fatty liver disease. <i>Journal of Biological Regulators and Homeostatic Agents</i> , 2011 , 25, 47-56	0.7	28
34	Effects of voriconazole on tacrolimus metabolism in a kidney transplant recipient. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2010 , 35, 121-4	2.2	32
33	High prevalence of nonalcoholic fatty liver in patients with idiopathic venous thromboembolism. <i>World Journal of Gastroenterology</i> , 2010 , 16, 6119-22	5.6	46
32	Absence of pharmacokinetic interference of moxifloxacin on cyclosporine and tacrolimus in kidney transplant recipients. <i>Journal of Clinical Pharmacology</i> , 2010 , 50, 576-80	2.9	7
31	Long-term assessment of plasma lipids in transplant recipients treated with tacrolimus in relation to fatty liver. <i>International Journal of Immunopathology and Pharmacology</i> , 2010 , 23, 1303-8	3	11
30	Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance. <i>World Journal of Gastroenterology</i> , 2010 , 16, 4773-83	5.6	130
29	Does spleen volume play a role in patients with HCV-related chronic hepatitis?. <i>International Journal of Immunopathology and Pharmacology</i> , 2009 , 22, 1009-17	3	6
28	Drug-induced liver injury due to "natural products" used for weight loss: a case report. <i>World Journal of Gastroenterology</i> , 2009 , 15, 2414-7	5.6	40
27	Circulating levels of interferon-gamma in course of hepatitis C virus-related arthritis. <i>Journal of Interferon and Cytokine Research</i> , 2009 , 29, 389-92	3.5	3
26	Relationships of PAI-1 levels to central obesity and liver steatosis in a sample of adult male population in southern Italy. <i>Internal and Emergency Medicine</i> , 2009 , 4, 315-23	3.7	22
25	Blood ammonia levels in liver cirrhosis: a clue for the presence of portosystemic collateral veins. <i>BMC Gastroenterology</i> , 2009 , 9, 21	3	66
24	What are the implications of the spontaneous spleno-renal shunts in liver cirrhosis?. <i>BMC Gastroenterology</i> , 2009 , 9, 89	3	72
23	Young adult obese subjects with and without insulin resistance: what is the role of chronic inflammation and how to weigh it non-invasively?. <i>Journal of Inflammation</i> , 2009 , 6, 6	6.7	55
22	EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects. <i>Fundamental and Clinical Pharmacology</i> , 2009 , 23, 617-24	3.1	25
21	Could inflammatory markers help diagnose nonalcoholic steatohepatitis?. <i>European Journal of Gastroenterology and Hepatology</i> , 2009 , 21, 504-11	2.2	133
20	Could high levels of tissue polypeptide specific antigen, a marker of apoptosis detected in nonalcoholic steatohepatitis, improve after weight loss?. <i>Disease Markers</i> , 2009 , 26, 55-63	3.2	3
19	Hepatic steatosis in overweight/obese females: new screening method for those at risk. <i>World Journal of Gastroenterology</i> , 2009 , 15, 5693-9	5.6	12
18	Could the depression of obese patients suffering from chronic hepatitis C be temporarily improved?. <i>Journal of Viral Hepatitis</i> , 2008 , 15, 646-50	3.4	3

17	Enhanced serum concentrations of transforming growth factor-beta1 in simple fatty liver: is it really benign?. <i>Journal of Translational Medicine</i> , 2008 , 6, 72	8.5	60
16	Can serum TGF-beta 1 be used to evaluate the response to antiviral therapy of haemophilic patients with HCV-related chronic hepatitis?. <i>International Journal of Immunopathology and Pharmacology</i> , 2008 , 21, 1007-12	3	9
15	Basal metabolic rate in morbidly obese patients with non-alcoholic fatty liver disease. <i>Clinical and Investigative Medicine</i> , 2008 , 31, E24-9	0.9	20
14	Non-alcoholic fatty liver disease, obesity and other illnesses. <i>Clinical and Investigative Medicine</i> , 2008 , 31, E290-5	0.9	8
13	Exaggerated immune reactions predict the outcome of interferon therapy in patients with chronic hepatitis C. <i>International Journal of Immunopathology and Pharmacology</i> , 2007 , 20, 837-40	3	2
12	Non-alcoholic fatty liver disease: further expression of the metabolic syndrome. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007 , 22, 293-303	4	123
11	Serum concentrations of the tissue polypeptide specific antigen in patients suffering from non-alcoholic steatohepatitis. <i>European Journal of Clinical Investigation</i> , 2007 , 37, 48-53	4.6	37
10	A pharmacokinetic interaction between clarithromycin and sirolimus in kidney transplant recipient. <i>Current Drug Metabolism</i> , 2007 , 8, 379-81	3.5	26
9	A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2007 , 37, 410-5	5.1	122
8	Extensive psoriasis induced by pegylated interferon: a case report. <i>Journal of Medical Case Reports</i> , 2007 , 1, 86	1.2	16
7	The contribution of omental adipose tissue to adipokine concentrations in patients with the metabolic syndrome. <i>Clinical and Investigative Medicine</i> , 2007 , 30, E192-9	0.9	15
6	Does protracted antiviral therapy impact on HCV-related liver cirrhosis progression?. <i>World Journal of Gastroenterology</i> , 2007 , 13, 4903-8	5.6	3
5	Reliability of total overnight salivary caffeine assessment (TOSCA) for liver function evaluation in compensated cirrhotic patients. <i>European Journal of Clinical Pharmacology</i> , 2006 , 62, 605-12	2.8	15
4	Metabolic factors involved in the therapeutic response of patients with hepatitis C virus-related chronic hepatitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006 , 21, 1266-8	4	42
3	HCV infection and chronic arthritis: Does viral replication matter?. <i>Hepatology Research</i> , 2006 , 35, 238-41	5.1	6
2	Abnormally high resistive index of central retinal artery by ultrasound color Doppler in patients with viral chronic liver disease: correlation with worsening liver staging. <i>Ultrasound in Medicine and Biology</i> , 2004 , 30, 599-604	3.5	7
1	Low daily dosage of interferon for 1 year after HCV-related end-therapy response. A randomized-controlled study. <i>Liver International</i> , 2003 , 23, 413-9	7.9	7